Corpus 1,275 assessed · 1,176 scored · 644 reproduced ≥75 · 170 flagged ·∅ 74.1/100

Publications 2 Datasets 392.5k Experiments 4.7k

Explore

Filters: 2024 ✕ 1 ✕ clinical-trial ✕ clear all

2 matching publication(s)

Publication	Journal	Year	Score	Verdict
Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials. PMID 39090192	NPJ Precis Oncol	2024	50	L1 50/100
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104). PMID 38897205	Cell Rep Med	2024	72	L1 72/100

Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials.

PMID 39090192 · NPJ Precis Oncol · 2024

L1 50/100

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).

PMID 38897205 · Cell Rep Med · 2024

L1 72/100